Board Appointment

Alliance Pharma PLC
10 January 2007



For immediate release                                            10 January 2007


                              ALLIANCE PHARMA PLC

                      ('Alliance Pharma' or 'the Company')


                               Board Appointment



Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
is pleased to announce that Mark John Tomlinson has been appointed as Medical
Director and that he will join the Company's Board with immediate effect as an
Executive Director.


Dr Tomlinson MB BCh, age 44, is a highly experienced pharmaceutical physician
with an international track record in the pharmaceutical industry where he has a
particular expertise in the management of clinical research projects and
preparing products for market.


Dr Tomlinson has worked at major pharmaceutical groups including Bristol-Myers
Squibb, where he held positions in the UK and US between 1996 and 2001, and at
Sanofi-Synthelabo, where he held the position of Head of Medical Affairs in the
UK during 2001 and 2002. Most recently Dr Tomlinson held the position of Medical
Director at Sequani Ltd, a clinical research organisation based in the UK which
he joined in 2003.


In parallel with his career in the pharmaceutical industry Dr Tomlinson has
continued his involvement with clinical practice in various part-time and
consultancy roles including acting as a GP Appraiser between 2003 and 2005 for
the Herefordshire Primary Care Trust.


Dr Tomlinson's appointment to the newly formed position of Medical Director at
Alliance Pharma will add significantly to Alliance's resources as it pursues the
development of Posidorm, its melatonin product for sleep disorders, and
Isprelor, its intra-vaginal misoprostol product for the induction of labour.



Michael Gatenby, Alliance Pharma's Chairman, said: 'I am delighted to welcome
Mark both to Alliance Pharma and to the Board. His breadth of experience gained
internationally in the pharmaceutical industry will be of significant value to
the Company's future development.'



There are no further disclosures to be made in accordance with Schedule 2 (g) of
the AIM rules.


For further information:
Alliance Pharma plc                                         + 44 (0) 1249 466966
                                                                          

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk
--------------------------

Buchanan Communications                                     + 44 (0)20 7466 5000
                                                                       

Mark Court/Lisa Baderoon/Rebecca Dietrich

Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a
strong track record of acquiring the rights to established niche brands and
owns, or shares, the rights to 34 branded pharmaceutical products and continues
to explore opportunities to expand the range.


Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers which
service both hospital and retail pharmacies with their prescription
requirements.


Alliance Pharma is also developing novel products for sleep disorders and the
induction of labour.

Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.




                      This information is provided by RNS
            The company news service from the London Stock Exchange